|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Z] 532 active entries
26 Corporate Circle
Albany, NY 12203, USA
United States of America, New York
Stock symbol: AMRI
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
AMRI is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development and manufacturing services. For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success and locations in North America, Europe and Asia provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline.
Inaugurated in 1991 as Albany Molecular Research, Inc., AMRI was founded by Thomas E. D’Ambra, Ph.D. and Chester Opalka. Dr. D’Ambra continues to serve as chairman, president and CEO. As AMRI, the company has been a publicly traded company on the NASDAQ since 1999.
AMRI SMARTSOURCING™ embraces every facet of drug discovery to help you put candidates in the clinic. You receive fully integrated, customer-focused services utilizing a collaborative and flexible approach to attain program goals. Embrace the entire drug discovery platform – including custom assay development and in vitro biology, DMPK, computational and medicinal chemistry, custom library synthesis and fragment-based drug discovery. Our dedicated project leadership team works on your behalf to coordinate activities and fully manage projects to meet critical timelines and handle all complexities during the discovery stage.
AMRI SMARTSOURCING™ provides state-of-the-art facilities and capabilities to deliver integrated pharmaceutical drug development programs through the clinic to commercial. We help clients assess and choose the best solid form for progression into animal and human dosing trials; our Pre-Formulation Development, Formulation Services & CTM, Process Development, and Analytical Services are available for a variety of dosage forms, from Powder-in-a-Bottle (PIB) and capsules to advanced oral, topical and sterile formulations. AMRI also has the capabilities required to provide a reliable and cost-effective supply of drug product through commercial production, as well as API from pre-clinical to post-NDA commercial production.
Backed by an excellent compliance history and track record, AMRI’s worldwide manufacturing facilities are equipped for Phase I through commercial API manufacturing. AMRI SMARTSOURCING™ also provides an added advantage as you move your compound from discovery to high potency manufacturing. Our global sites in the United States, Europe and Asia are positioned to provide tailored solutions and to enable the efficient, cost-effective transfer of pre-clinical and commercial drug products – from small-scale to large-scale production. We can provide raw materials, starting materials and cGMP manufacturing of API. We have an experienced staff utilizing substantial global capacity.
Aseptic Fill and Finish
As part of its fully integrated global contract services offering, AMRI provides aseptic manufacturing services. In the company’s state-of-the art cGMP manufacturing facility, in Burlington, Mass., AMRI offers customers aseptic processing services, including aseptic filling of syringes, vials and other custom containers; lyophilization; and the very latest in Stability Optimization Services (SOS). AMRI supports clients from pre-clinical stages of development through cGMP clinical and commercial scale production of liquid-filled parenterals.
AMRI works with large global and small-to-medium-size biotech/specialty pharmaceutical companies, and government and nonprofit organizations.
Last update of this entry: July 09, 2013